Claire Bony
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Claire Bony has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Danièle Noël
IRMB, Univ Montpellier, INSERM, Montpellier, France
3 shared publications A. Abergel
Department of Visceral and Vascular Radiology, CHU Montpied, Clermont-Ferrand, France, Department of Gastroenterology and Department of Digestive Surgery, Hôtel Dieu CHU, Clermont-Ferrand, France, Department of Interventional Radiology, Gustave Roussy Institute, Villejuif, France
1 shared publicationA. Alfidja
Department of Visceral and Vascular Radiology, CHU Montpied, Clermont-Ferrand, France
1 shared publicationA. Ravel
Department of Visceral and Vascular Radiology, CHU Montpied, Clermont-Ferrand, France, Department of Gastroenterology and Department of Digestive Surgery, Hôtel Dieu CHU, Clermont-Ferrand, France, Department of Interventional Radiology, Gustave Roussy Institute, Villejuif, France
1 shared publication- Ann M. Roche
National Centre for Education and Training on Addiction, Flinders University, South Australia
1 shared publication - Anne Wojtusciszyn
Centre Hospitalier de Montpellier, Pôle Rein Hypertension Métabolisme, Service d'Endocrinologie, Montpellier, France
1 shared publication
Latest Publications
- 13 September 2022
- Published by Elsevier in Acta Biomaterialia
- Vol. 153, 97-107
Size-tunable lipid vectors for controlled local delivery of siRNA from gene activated matrix
- 13 September 2022
- Published by Elsevier in Acta Biomaterialia
- Vol. 153, 97-107
Size-tunable lipid vectors for controlled local delivery of siRNA from gene activated matrix
- Open Access
- 21 May 2020
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 11 (1) , 1
Correction to: Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features
An amendment to this paper has been published and can be accessed via the original article.
- 21 May 2020
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 11 (1) , 1
Open AccessCorrection to: Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features
An amendment to this paper has been published and can be accessed via the original article.
- Open Access
- 6 November 2017
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 12 (4) , 1062-1073
Mesenchymal stem cells seeded on a human amniotic membrane improve liver regeneration and mouse survival after extended hepatectomy
Liver failure remains the leading cause of post‐operative mortality after hepatectomy. This study investigated the effect of treatment with allogenic mesenchymal stem cells (MSCs) on survival and liver regeneration 48 hr and 7 days after 80% hepatectomy in C57Bl/6 mice. To optimize their biodistribution, MSCs were grown on acellular human amniotic membranes (HAM) and applied as a patch on the remnant liver. This approach was compared with MSC infusion and HAM patch alone. Hepatectomized mice without any treatment were used as control group. Survival rate was calculated and biological and histopathological parameters were analysed to monitor liver function and regeneration. MSCs grown on HAM retained their ability to proliferate, to differentiate into osteoblasts and adipocytes and to respond to pro‐inflammatory stimuli. Extended hepatectomy (80%) led to liver failure that resulted in death within 72 hr in 76% of mice. MSC infusion showed an early but transitory positive effect on survival. MSC/HAM patches stimulated regeneration and significantly improved survival rate (54% vs. 24% in the control group at 7 days). They also decreased the severity of hepatectomy‐induced steatosis, suggesting a modulation of lipid metabolism in hepatocytes. MSCs were still present on HAM at Days 2 and 7 posthepatectomy. In conclusion, engineered tissue constructs that combine MSCs and HAM improve survival and liver regeneration after 80% hepatectomy in mice. These encouraging results pave the way to potential clinical application.
- 6 November 2017
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 12 (4) , 1062-1073
Open AccessMesenchymal stem cells seeded on a human amniotic membrane improve liver regeneration and mouse survival after extended hepatectomy
Liver failure remains the leading cause of post‐operative mortality after hepatectomy. This study investigated the effect of treatment with allogenic mesenchymal stem cells (MSCs) on survival and liver regeneration 48 hr and 7 days after 80% hepatectomy in C57Bl/6 mice. To optimize their biodistribution, MSCs were grown on acellular human amniotic membranes (HAM) and applied as a patch on the remnant liver. This approach was compared with MSC infusion and HAM patch alone. Hepatectomized mice without any treatment were used as control group. Survival rate was calculated and biological and histopathological parameters were analysed to monitor liver function and regeneration. MSCs grown on HAM retained their ability to proliferate, to differentiate into osteoblasts and adipocytes and to respond to pro‐inflammatory stimuli. Extended hepatectomy (80%) led to liver failure that resulted in death within 72 hr in 76% of mice. MSC infusion showed an early but transitory positive effect on survival. MSC/HAM patches stimulated regeneration and significantly improved survival rate (54% vs. 24% in the control group at 7 days). They also decreased the severity of hepatectomy‐induced steatosis, suggesting a modulation of lipid metabolism in hepatocytes. MSCs were still present on HAM at Days 2 and 7 posthepatectomy. In conclusion, engineered tissue constructs that combine MSCs and HAM improve survival and liver regeneration after 80% hepatectomy in mice. These encouraging results pave the way to potential clinical application.
- 1 March 2006
- Published by SAGE Publications in Acta Radiologica
- Vol. 47 (2) , 130-134
Portal vein stenosis and occlusion stenting after liver transplantation in two adults
We report two cases of percutaneous transhepatic stenting of the portal vein to treat stenosis and occlusion disclosed 5 and 18 months, respectively, after orthotopic liver transplantation in two adult patients. If long-term patency is satisfactory, this technique should allow long-term management of portal vein stenosis and occlusion without the use of thrombolysis.
- 1 March 2006
- Published by SAGE Publications in Acta Radiologica
- Vol. 47 (2) , 130-134
Portal vein stenosis and occlusion stenting after liver transplantation in two adults
We report two cases of percutaneous transhepatic stenting of the portal vein to treat stenosis and occlusion disclosed 5 and 18 months, respectively, after orthotopic liver transplantation in two adult patients. If long-term patency is satisfactory, this technique should allow long-term management of portal vein stenosis and occlusion without the use of thrombolysis.